{"schema_version":"1","generated_at":"2026-11-04T17:35:10.984Z","data_as_of":null,"url":"https://www.findmykol.com/kol/shagun-arora","json_url":"https://www.findmykol.com/kol/shagun-arora/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"shagun-arora","name":"Shagun Arora","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"University of California, San Francisco","institution_url":"https://www.findmykol.com/institution/university-of-california-san-francisco","city":"San Francisco","state":"CA","region":{"label":"West","url":"https://www.findmykol.com/region/west"}},"identifiers":{"npi":"1316198112","orcid":"0000-0002-6184-1968","openalex":"A5083698821"},"summary":"Shagun Arora is an Oncology physician affiliated with University of California, San Francisco. OpenAlex indexes 62 publications with 381 citations (h-index 10).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":62,"cited_by_count":381,"h_index":10,"latest_activity_year":2026,"source":"works"},"payments":{"company_count":2,"program_years":{"first":2021,"last":null},"rows_total":3,"shown":3,"withheld":0,"rows":[{"payer":"ABBVIE INC.","program_year":2024,"amount_usd":25.16,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1316198112"},{"payer":"Pharmacyclics LLC, An AbbVie Company","program_year":2023,"amount_usd":16.66,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1316198112"},{"payer":"Pharmacyclics LLC, An AbbVie Company","program_year":2021,"amount_usd":99,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1316198112"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1316198112","source":"payments"},"prescribing":{"data_year":2023,"areas_total":5,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":42.2,"classes_total":2,"classes":[{"class":"Thalidomide Analog","setting":"prescribed","share_pct":35.5,"drugs":[{"name":"Revlimid","share_pct":80},{"name":"Lenalidomide","share_pct":20}],"max_beneficiaries":null},{"class":"Kinase inhibitor","setting":"prescribed","share_pct":6.6,"drugs":[{"name":"Brukinsa","share_pct":100}],"max_beneficiaries":null}]},{"area":"Anti-infectives","share_pct":23.2,"classes_total":2,"classes":[{"class":"Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor","setting":"prescribed","share_pct":18,"drugs":[{"name":"Valacyclovir","share_pct":100}],"max_beneficiaries":null},{"class":"Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor","setting":"prescribed","share_pct":5.2,"drugs":[{"name":"Entecavir","share_pct":100}],"max_beneficiaries":null}]},{"area":"Dermatology","share_pct":22.7,"classes_total":1,"classes":[{"class":"Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor","setting":"prescribed","share_pct":22.7,"drugs":[{"name":"Acyclovir","share_pct":100}],"max_beneficiaries":22}]}],"care_setting":{"dominant":"facility","data_year":2023,"office_pct":8.2,"facility_pct":91.8},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"How long is long enough? Outcomes with finite-duration bispecific antibody therapy in multiple myeloma.","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.7538","status":"verified"},{"title":"GPRC5D‐targeting bispecific and trispecific antibodies in multiple myeloma: Current evidence and emerging strategies","year":2026,"journal":"Cancer","source_url":"https://doi.org/10.1002/cncr.70597","status":"verified"},{"title":"Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenström macroglobulinemia treated with venetoclax: a multicenter retrospective analysis","year":2025,"journal":"Blood Cancer Journal","source_url":"https://doi.org/10.1038/s41408-025-01271-3","status":"verified"},{"title":"Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review","year":2025,"journal":"Expert Opinion on Investigational Drugs","source_url":"https://doi.org/10.1080/13543784.2025.2511179","status":"verified"},{"title":"Impact of prior BCMA-targeted therapy on CAR-T expansion and host T-cell phenotypes in patients with Relapsed/Refractory multiple myeloma receiving BCMA CAR-T therapy","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2025-3916","status":"verified"}],"source":"works"},"contact":{"address_1":"400 PARNASSUS AVE FL 4","city":"San Francisco","state":"CA","zip":"941432202","phone":"415-353-2421","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1316198112","source":"identity"},"similar":[{"name":"Talmadge King","slug":"talmadge-king","institution":"University of California, San Francisco","specialty":"Pulmonary Disease","url":"https://www.findmykol.com/kol/talmadge-king","json_url":"https://www.findmykol.com/kol/talmadge-king/profile.json"},{"name":"Adil Daud","slug":"adil-daud","institution":"University of California, San Francisco","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/adil-daud","json_url":"https://www.findmykol.com/kol/adil-daud/profile.json"},{"name":"Emmanuelle Waubant","slug":"emmanuelle-waubant","institution":"University of California, San Francisco","specialty":"Neurology","url":"https://www.findmykol.com/kol/emmanuelle-waubant","json_url":"https://www.findmykol.com/kol/emmanuelle-waubant/profile.json"},{"name":"Peter Ganz","slug":"peter-ganz","institution":"University of California, San Francisco","specialty":"Cardiovascular Disease","url":"https://www.findmykol.com/kol/peter-ganz","json_url":"https://www.findmykol.com/kol/peter-ganz/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2022-07-26","provider_certified":"2022-07-26","collected_at":"2026-11-04T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}